Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Human Biologicals Institute (HBI) is a prominent biotechnology division of Indian Immunologicals Limited (IIL), established to address critical public health needs through the development of affordable vaccines. The institute is best known for its flagship product, Abhayrab, which was the first indigenous tissue-culture-based anti-rabies vaccine in India and has become one of the most widely used rabies vaccines globally. HBI operates advanced manufacturing facilities in Ooty and Hyderabad, specializing in the production of essential pediatric and adult vaccines including DPT, Tetanus Toxoid, and Hepatitis B. As a key contributor to India's Universal Immunization Programme, HBI focuses on high-volume production of WHO-prequalified biologicals for both domestic and international markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Human Biologicals Institute.